ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
Laboratory experiments have shown niclosamide stops…
Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020.
Group Financial Highlights
Reported revenue of £22.4m (HY19: £26.1m)1 down 13.9% (15.5% on a constant currency basis) largely due to impact of COVID-19 pandemic and a rapid reduction of academic research work in Q2 2020…
Westbury, NY – Aug. 14, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is now offering same- or next-day delivery of fresh blood and immune cell products from its seven blood donor centers, which are strategically located near biopharma hubs in the US and UK, to almost anywhere in the world.
“We are always looking for new ways to help our clients to optimize their cell and gene therapy, drug and in-vitro diagnostic research. Delivering high quality, fresh blood and immune cell products within hours of collection…
While pharmaceuticals contribute to approximately 2% of annual air cargo volume, the industry transports over one trillion dollars’ worth of cargo every year (IATA). Pharmaceutical shipments have an overwhelmingly large impact on the global response to infectious diseases and general healthcare.
COVID-19 has shown that effective healthcare logistics management requires not only regulatory expertise and extensive planning, but also a proactive global network of logistics experts who can respond to last-minute changes, namely flight cancellations and lockdowns.
British Airways recently…
CRISPR-based screening technology platform to address critical gaps in target ID and validation
Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight
Cambridge, UK, 04 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company", or "the Group"), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio. The platform offers high-quality screening data and…
Chesterford Research Park management team and Diagnostics for the Real World work together, re-purposing space to create efficient assembly line
Cambridge, UK, 6th August 2020: Chesterford Research Park based Diagnostics for the Real World (DRW) made worldwide headlines earlier this year with a game-changing way of testing for COVID-19. The University of Cambridge spinout responded quickly to the pandemic by adapting its HIV testing machine, SAMBA II, to diagnose COVID-19 infection in just 90 minutes. Having first been used at Addenbrookes Hospital in Cambridge the…
£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park
Science Park helping to drive local economic growth with SELEP support
Sandwich, Kent, August 4 2020 – Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has been awarded £2.5m towards accelerated delivery of its Incubator facility by the South East Local Enterprise Partnership (SELEP). The grant, which comes from SELEP’s £85m share of the Government’s new Getting Building Fund, will be used to create flexible laboratory, write-up and office space for…
Situation:
The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.
Our position:
At Richmond Research Institute (RRI), as a not-for-profit clinical research organisation focused on medicines and patient safety, we were acutely aware we had access to resources and expertise we could re-deploy to start COVID-19 testing quickly. Originally born out of the necessity to protect and enable…
Where next for UK life sciences regulation?, Where next for the EU’s pharmaceutical strategy? International data transfers after the demise of the US Privacy Shield, Supply chain resilience, and much more…..
Sequence - July 2020 - Issue 11
- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions
- Scientists can participate until October 31, 2020
- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017
AlmirallShare, the open innovation platform of Almirall, S.A. (ALM), launches its fifth call, aiming to establish collaborations in dermatological…